Use of ctDNA for the Detection of Minimal Residual Disease in the Adjuvant Setting, Technical & Clinical Challenges: Are We There Yet?

Time: 8:30 am
day: Day One

Details:

• What do we need to test new cancer therapies in the adjuvant space?
• What are the potential pitfalls?

Speakers: